Miragen Therapeutics Inc Share Price Cinnober Boat
Stocks
US60463E1038
Biotechnology & Medical Research
| Market Cap | 2.53B 0 2.17B 2.05B 1.87B 3.49B 241B 3.52B 24.4B 9.39B 122B 9.48B 9.28B 389B | P/E 2026 * |
-5.62x | P/E 2027 * | -8.64x |
|---|---|---|---|---|---|
| Enterprise Value | 1.74B 0 1.49B 1.41B 1.28B 2.4B 166B 2.42B 16.8B 6.46B 84.29B 6.53B 6.38B 268B | EV / Sales 2026 * |
62.2x | EV / Sales 2027 * | 8.74x |
| Free-Float |
99.32% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Miragen Therapeutics Inc
| Manager | Title | Age | Since |
|---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 55 | 29/10/2023 |
Seth Harmon
DFI | Director of Finance/CFO | 46 | 11/09/2023 |
Kirk Bertelsen
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 74 | 02/01/2018 |
Tomas Kiselak
CHM | Chairman | 39 | 31/05/2021 |
Jennifer Moses
BRD | Director/Board Member | 51 | 13/07/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -.--% | -.--% | - | - | 2.58B | |
| -0.56% | -8.08% | -3.88% | +10.58% | 46.38B | |
| -2.08% | -3.57% | +402.72% | +533.09% | 44.51B | |
| +0.12% | -5.27% | +39.94% | +20.50% | 42.3B | |
| -2.62% | -5.76% | +8.88% | +77.44% | 39.91B | |
| -1.26% | -3.37% | +11.87% | +40.55% | 32.79B | |
| +0.16% | -3.65% | - | - | 17.13B | |
| -0.54% | -1.72% | +22.34% | +115.10% | 16.36B | |
| -0.03% | -3.46% | +12.68% | +30.90% | 14.31B | |
| -1.92% | -6.94% | +78.12% | +36.68% | 13.29B | |
| Average | -0.87% | -4.30% | +71.58% | +108.10% | 29.66B | |
| Weighted average by Cap. | -1.08% | -4.54% | +87.11% | +129.36% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 27.92M 0 24.01M 22.66M 20.64M 38.59M 2.67B 38.94M 270M 104M 1.35B 105M 103M 4.3B | 232M 0 199M 188M 171M 320M 22.14B 323M 2.24B 861M 11.23B 870M 851M 35.67B |
| Net income | -466M -0 -401M -378M -344M -644M -44.56B -650M -4.5B -1.73B -22.6B -1.75B -1.71B -71.78B | -322M -0 -277M -261M -238M -445M -30.78B -449M -3.11B -1.2B -15.61B -1.21B -1.18B -49.59B |
| Net Debt | -787M -0 -677M -639M -582M -1.09B -75.25B -1.1B -7.61B -2.93B -38.17B -2.96B -2.89B -121B | -501M -0 -431M -407M -371M -693M -47.92B -699M -4.84B -1.86B -24.31B -1.88B -1.84B -77.2B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
